These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 8231477)

  • 1. [The EEC creates a European Medical Product Agency].
    Johnson K
    Lakartidningen; 1993 Oct; 90(40):3395. PubMed ID: 8231477
    [No Abstract]   [Full Text] [Related]  

  • 2. [Europe 1993 and drugs].
    Reuse J
    Bull Mem Acad R Med Belg; 1990; 145(8-9):341-9; discussion 349-50. PubMed ID: 2099233
    [No Abstract]   [Full Text] [Related]  

  • 3. The International Conference on Harmonization common technical document--global submission format?
    Molzon JA
    Food Drug Law J; 2005; 60(3):447-51. PubMed ID: 16304749
    [No Abstract]   [Full Text] [Related]  

  • 4. The shape of European business in 2003.
    Wagner M
    Med Device Technol; 2002 Dec; 13(10):8-10. PubMed ID: 12575520
    [No Abstract]   [Full Text] [Related]  

  • 5. Counterfeiting and piracy of pharmaceuticals.
    Grackin A
    IEEE Eng Med Biol Mag; 2008; 27(6):66-9. PubMed ID: 19004698
    [No Abstract]   [Full Text] [Related]  

  • 6. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
    Purnhagen KP
    Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663
    [No Abstract]   [Full Text] [Related]  

  • 7. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
    Ainsworth MA
    Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [European drug market--dream or nightmare?].
    Nord Med; 1974 Jan; 89(1):6-8. PubMed ID: 4819431
    [No Abstract]   [Full Text] [Related]  

  • 10. Extension of the EEC pharmaceutical legislation to allergens.
    Brunko P; Sauer F
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 1992; (85):41-53. PubMed ID: 1540296
    [No Abstract]   [Full Text] [Related]  

  • 11. Double standards in GMP deduplication row.
    Hodgson J; Fox JL
    Nat Biotechnol; 1996 Dec; 14(13):1647-8. PubMed ID: 9634839
    [No Abstract]   [Full Text] [Related]  

  • 12. The industry moves confidently into 2006.
    This, the third of a three-part series reporting findings of Medical Device Technology's 2005 European market survey, highlights trends in manufacturing. The conclusions point to a positive coming year for the industry, which is confident in its growth strategy
    Med Device Technol; 2005 Dec; 16(10):34-6. PubMed ID: 16419926
    [No Abstract]   [Full Text] [Related]  

  • 13. [European efforts in drug problems].
    Bertschinger JP
    Ther Umsch; 1971 Apr; 28(4):220-5. PubMed ID: 5575079
    [No Abstract]   [Full Text] [Related]  

  • 14. [The "responsible pharmacist" in Europe: is there a French exception?].
    Chalchat B
    Ann Pharm Fr; 2002 Sep; 60(5):352-5. PubMed ID: 12378147
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacovigilance: an opportunity for the European Commission to put patients' interests first.
    Prescrire Int; 2010 Jun; 19(107):141. PubMed ID: 20738052
    [No Abstract]   [Full Text] [Related]  

  • 16. [The industrialisation of therapeutic agents: a story of practices between science, technology, medicine and the law].
    Gaudillière JP
    Gesnerus; 2007; 64(1-2):93-108. PubMed ID: 17982961
    [No Abstract]   [Full Text] [Related]  

  • 17. The expectations of the medical profession concerning the EEC directives for allergenic extracts.
    Fuchs E
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 1992; (85):19-22; discussion 22-3. PubMed ID: 1540292
    [No Abstract]   [Full Text] [Related]  

  • 18. [Mutual recognition: experiences and problems in various countries].
    Van den Eede C
    Tijdschr Diergeneeskd; 1998 Jan; 123(2):54-6. PubMed ID: 9537076
    [No Abstract]   [Full Text] [Related]  

  • 19. ISO 9000. Policy implications for FDA. Taking the pulse of increasing global use of the ISO series of uniform quality standards by FDA regulated industries.
    Schwemer WL; Lynch MA
    J Parenter Sci Technol; 1993; 47(3):101-18. PubMed ID: 8360802
    [No Abstract]   [Full Text] [Related]  

  • 20. Inspections: the international regulatory view.
    Turner JL
    PDA J Pharm Sci Technol; 1994; 48(4):180-1. PubMed ID: 7804815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.